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Control of FLIPL expression and TRAIL resistance by
the extracellular signal-regulated kinase1/2 pathway
in breast epithelial cells
R Yerbes1, A Lo´pez-Rivas*,1, MJ Reginato2 and C Palacios*,1
Increased activation of the epidermal growth factor receptor (EGFR) is frequently observed in tumors, and inhibition of the
signaling pathways originated in the EGFR normally renders tumor cells more sensitive to apoptotic stimuli. However, we show
that inhibition of EGFR signaling in non-transformed breast epithelial cells by EGF deprivation or gefitinib, an inhibitor of EGFR
tyrosine kinase, causes the upregulation of the long isoform of caspase-8 inhibitor FLICE-inhibitory protein (FLIPL) and makes
these cells more resistant to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). We demonstrate that the
extracellular signal-regulated kinase (ERK)1/2 pathway plays a pivotal role in the regulation of FLIPL levels and sensitivity to
TRAIL-induced apoptosis by EGF. Upregulation of FLIPL upon EGF deprivation correlates with a decrease in c-Myc levels and
c-Myc knockdown by siRNA induces FLIPL expression. FLIPL upregulation and resistance to TRAIL in EGF-deprived cells are
reversed following activation of an estrogen activatable form of c-Myc (c-Myc-ER). Finally, constitutive activation of the ERK1/2
pathway in HER2/ERBB2-transformed cells prevents EGF deprivation-induced FLIPL upregulation and TRAIL resistance.
Collectively, our results suggest that a regulated ERK1/2 pathway is crucial to control FLIPL levels and sensitivity to TRAIL in
non-transformed cells, and this mechanism may explain the increased sensitivity of tumor cells to TRAIL, in which the ERK1/2
pathway is frequently deregulated.
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Tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL) is a ligand of the TNF family capable of
inducing apoptosis in a wide variety of cancer cells upon
binding to pro-apoptotic receptors, but with no effect in the
majority of normal human cells tested.1 This unique char-
acteristic of TRAIL is currently being exploited as a potential
antitumor therapy.2 Activation of TRAIL receptors (TRAIL-Rs)
leads to the formation of the death-inducing signaling complex
(DISC), which includes the receptor itself, the adapter
molecule Fas-associated death domain (FADD) and procas-
pase-8.3,4 Processing and activation of caspase-8 at the DISC
leads to a cascade of apoptotic events resulting in cell death.
At the DISC level, the apoptotic signal may be inhibited by
cellular FLICE-inhibitory protein (cFLIP), the homolog of viral
FLIP (vFLIP) in vertebrate cells.5 In most cells, cFLIP exists
as two alternative spliced isoforms: FLIPL, a homolog
of caspase-8 that lacks critical amino acids for proteolytic
caspase activity, and cFLIPS, consisting only of two death
effector domains (DED).5 Although the role of FLIPL as an
inhibitor of apoptotic signaling has been controversial,6,7
recent data indicate that heterodimerization of FLIPL with
procaspase-8 induces limited caspase-8 activation, prevent-
ing further transduction of the apoptotic signal.8 FLIP
expression fluctuates in a cell-type-specific manner and in
response to various stimuli, transcriptionally through the
NF-kB pathway,9 and at the protein level via altered rates of
proteasomal degradation,10 which makes it a versatile
inhibitor of apoptotic responses mediated by death receptors.
Binding of epidermal growth factor (EGF) to its monomeric
receptor (EGFR) activates homo/heterodimerization and self-
phosphorylation on tyrosine residues, which are used by
docking proteins to engage molecules involved in different
signaling pathways.11 Activation of the Ras-dependent extra-
cellular signal-regulated kinase (ERK)1/2 mitogen-activated
protein kinase (MAPK) pathway by EGF in normal cells is
required for efficient G1- to S-phase transition and for the
control of cell proliferation.12 Upon activation, ERK1/2
translocates to the nucleus and phosphorylates the ternary
complex factor, which in turn induces the transcription of
immediate-early genes like c-Fos and c-Myc.13,14 Prolonged
ERK activation results in c-fos and c-myc phosphorylation,
stabilizing these transcription factors and thereby promoting
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activation of the G1-specific cyclin-dependent kinases and
cell cycle entry.15,16
In many human cancers, including breast carcinoma,
EGFR overexpression is correlated with cellular proliferation,
angiogenesis and tumor growth, leading to invasiveness and
metastasis,17 thus providing a potential target for therapy.18
In several tumor cell types, activation of the EGFR induces
resistance to different apoptotic stimuli, including TRAIL,19
due to activation of the phosphatidyl inositol 3-kinase (PI3K)/
AKT pathway. However, despite all the available evidences in
tumor cells, the regulation of TRAIL sensitivity by EGFR
signaling in non-tumor cells remains to be investigated.
We report here that EGFR activation downregulates cFLIP
expression and enhances the sensitivity of non-transformed
human breast epithelial cells to TRAIL-induced apoptosis.
Our results also indicate that cFLIP levels and TRAIL
sensitivity are both controlled by the EGFR-mediated regula-
tion of the ERK1/2 pathway and c-myc expression. In addition,
we show that deregulated ERK1/2 activation in human breast
epithelial cells transformed with the oncogene Her2/ERBB2
prevents EGF deprivation-induced FLIPL upregulation and
TRAIL resistance, underlining the relevance of this pathway
in controlling TRAIL-induced apoptosis.
Results
EGF controls the sensitivity of human breast epithelial
cells to TRAIL-promoted apoptosis at the apical level in
TRAIL-R signaling. In the past years, several compounds
targeting the EGFR have been developed to treat advanced
cancers.18 Moreover, inhibition of EGFR signaling syner-
gizes with TRAIL in the induction of apoptosis in tumor
cells.20 However, cross-talk between EGFR and TRAIL-R
signaling has not been investigated in non-tumor cells.
To address this issue, we determined the effect of EGF
deprivation on the apoptotic response to TRAIL in non-tumor
breast epithelial cell lines. Results depicted in Figure 1a and
Supplementary Figure S1A and S1C demonstrate that
preventing EGFR signaling by EGF deprivation induced
resistance to TRAIL. These results we confirmed with
gefitinib, an inhibitor of the EGFR tyrosine kinase and EGFR
signaling.21 Incubation of MCF10A cells in EGF-containing
medium (CM) with gefitinib completely inhibited TRAIL-
induced apoptosis (Supplementary Figure S2A), further
indicating that EGFR activation facilitates TRAIL-induced
apoptosis in non-tumor cells.
Activation of pro-apoptotic receptors by TRAIL induces
apical procaspase-8 cleavage to generate the small subunit,
p12, and the p43/41 intermediate fragment, which is subse-
quently processed to produce the large catalytically active p18
subunit.4 We determined the processing of procaspase-8 in
MCF10A cells treated with TRAIL following culture of cells
in the presence or absence of EGF. Procaspase-8 cleavage to
generate its 43–41 kDa intermediate fragments, and the
subsequent generation of p18 subunit upon TRAIL-R activa-
tion weremarkedly inhibited in MCF10A cells deprived of EGF
(Figure 1b).
Upregulation of FLIPL upon EGF deprivation confers
resistance to TRAIL. Expression levels of DISC proteins
such as TRAIL-R2, FADD or procaspase-8 did not change
following EGF deprivation in MCF10A cells (Figures 1c and
d), indicating that a reduction of pro-apoptotic DISC
components was not the mechanism underlying the dimin-
ished caspase-8 activation by TRAIL in EGF-deprived cells.
Interestingly, EGF withdrawal caused the upregulation of the
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Figure 1 EGF deprivation induces resistance to TRAIL-induced apoptosis at the apical level. (a) MCF10A cells grown in the presence or absence of 20 ng/ml EGF during
48 h were treated with or without TRAIL (500 ng/ml) for 6 h. Apoptosis was then measured as described in Materials and Methods. Error bars represent S.D. from three
independent experiments. *Po0.05. (b) MCF10A cells were grown in the presence or absence of EGF for 48 h before adding TRAIL (1mg/ml). Cells were incubated with
TRAIL for the indicated times and activation of caspase-8 was assessed by western blotting. In the TRAIL-untreated samples ,FLIPL, FLIPS, TRAIL-R2, procaspase-8 and
FADD levels were also determined. (c) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a protein loading control. Results are representative of two
independent experiments. (d) Cells incubated with ( ) or without EGF (—) for 48 h were harvested and cell surface expression of TRAIL-R1 and TRAIL-R2 receptors
assessed by flow cytometry as described in Materials and Methods. Cells incubated with FITC-labeled secondary antibody alone were used as a control for background
fluorescence of cells cultured in the presence (.....) or absence (- - - -) of EGF. Results are representative of two independent experiments
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long form of cFLIP (FLIPL) in non-transformed breast
epithelial cells (Figure 1c and Supplementary Figures S1B
and S1D), suggesting a possible role of this inhibitor in the
enhanced resistance to TRAIL of cells deprived of EGF.
Furthermore, inhibition of EGFR signaling with gefinitib
markedly upregulated FLIPL expression in MCF10A cells
(Supplementary Figure S2B), confirming that EGFR activa-
tion by EGF is involved in the regulation of FLIPL levels in
non-transformed breast epithelial cells. In contrast, depriva-
tion of either insulin or hydrocortisone, two medium additives
for optimal growth of MCF10A cells,22 did not upregulate
FLIPL expression (Supplementary Figure S2C).
Time-course analysis of FLIPL levels following EGF
deprivation (Figure 2a, left panel) indicated that FLIPL, but
not FLIPS, markedly accumulated in MCF10A cells between
40 and 72 h after EGF removal. FLIPL levels slightly increased
after 72 h incubation in the presence of EGF (Figure 2a, right
panel), which was associated to a reduction in EGFR
signaling as determined by the inhibition of ERK1/2 phos-
phorylation, most likely reflecting the impact of cell density on
EGFR signaling as reported recently.23 We next determined
whether the upregulation of FLIPL protein seen in EGF-
deprived cells was also observed at the mRNA level.
RT-qPCR analysis of mRNA levels demonstrated that EGF
deprivation induced a marked upregulation of FLIPL mRNA
starting at 40 h after EGF withdrawal (Figure 2b). Strikingly, a
strong correlation was observed between the decrease in
EGFR signaling (ERK1/2 phosphorylation) and the increased
expression of FLIPL and resistance of MCF10A cells to TRAIL
following EGF deprivation (Figures 2a and c).
As FLIPL levels are important determinants of the sensitivity
of breast tumor and non-tumor epithelial cells to TRAIL-
induced apoptosis,24,25 we then assessed whether silencing
FLIPL expression could sensitize EGF-deprived cells to
TRAIL. Interestingly, FLIPL knockdown (Figure 3a, upper
panel) was sufficient to prevent the induction of TRAIL
resistance in EGF-deprived cells (Figure 3a, lower panel),
indicating the importance of FLIPL accumulation in the
acquired resistance to TRAIL after EGF withdrawal. Further-
more, in cells stably overexpressing FLIPL (Figure 3b, upper
panel), TRAIL-induced apoptosis was clearly inhibited in
EGF-CM (Figure 3b, lower panel). Our results supported an
important role of EGF-regulated FLIPL levels in the resistance
of non-transformed breast epithelial cells to TRAIL-induced
apoptosis.
Role of the ERK1/2 pathway in the control of FLIPL levels
and TRAIL resistance in breast epithelial cells. Upon
EGFR activation by EGF, the MAPK/ERK and the PI3K/Akt
pathways, among others, are activated to produce a
physiological outcome.11 To investigate the role of these
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resistance to TRAIL. Analysis by western blotting (a) or quantitative PCR (b) of
FLIPL and FLIPS levels in MCF10A cells deprived of EGF for the indicated times.
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Figure 3 Role of FLIPL in EGF deprivation-promoted resistance to
TRAIL-induced apoptosis. (a) MCF10A cells were transfected either with a small
interfering RNA (siRNA) oligonucleotide targeting FLIPL (FL) or a scrambled (SC)
oligonucleotide for 24 h as described in Materials and Methods. Thereafter, cells
were incubated in the presence or absence of EGF for 24 h before treatment
with soluble TRAIL (500 ng/ml) for 6 h. Apoptosis was measured as in Figure 1.
Error bars represent S.D. from three independent experiments. ***Po0.001. FLIPL
knockdown was assessed by western blotting and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a protein loading control. (b) MCF10A cells
were infected with retroviruses encoding control vector (pBabe Mock) or FLIPL.
Following puromycin selection for stably infected cell lines, cells were treated with
soluble TRAIL (500 ng/ml) for 6h in the presence of EGF. Apoptosis was measured
as in Figure 1. Error bars represent S.D. from three independent experiments.
***Po0.001. FLIPL levels were assessed by western blotting and GAPDH was
used as a protein loading control
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pathways in the control of FLIPL levels, we assessed the
effect of the inhibitors U0126 (MAPK pathway) and
LY294002 (PI3K/Akt pathway) on the regulation of FLIPL
levels by EGF. Re-addition of either EGF-CM or EGF alone
to EGF-deprived cells induced a marked downregulation of
FLIPL expression in MCF10A cells (Supplementary Figure
S2D). Downregulation of FLIPL after re-addition of CM to
EGF-deprived cells was not blocked by LY294002
(Figure 4a), although AKT was significantly inhibited, which
indicated that the PI3K/Akt pathway was not involved in
FLIPL regulation by EGFR signaling in MCF10A cells. In
contrast to the lack of involvement of the PI3K/Akt pathway in
the regulation of FLIPL expression by EGF, the results
depicted in Figure 4b (upper panel) and Supplementary
Figure S1B and S1D demonstrated that the ERK1/2 pathway
played an important role in the downregulation of FLIPL
expression following EGFR activation in several non-tumor
breast epithelial cell lines. Thus, inhibition of the ERK1/2
pathway by the MAPK/ERK kinase 1 (MEK1) inhibitor U0126
blocked FLIPL downregulation induced by EGF re-addition
to EGF-deprived cells. Levels of the pro-apoptotic BH3-only
protein BimEL levels are shown as control of a protein
negatively regulated by the ERK1/2 pathway in these cells.26
Furthermore, EGF-induced regulation of FLIPL expression by
the ERK1/2 pathway occurred also at the mRNA level, as the
presence of U0126 during EGF re-addition to EGF-deprived
cells blocked, at least in part, FLIPL mRNA downregulation
(Figure 4b, lower panel). Importantly, inhibition of the ERK1/2
pathway prevented the restoration of sensitivity to TRAIL
upon EGF re-addition to EGF-deprived cells (Figure 4c and
Supplementary Figure S1A).
To further demonstrate the role of the ERK1/2 pathway
in EGFR-mediated regulation of FLIPL expression, we
generated MCF10A cells overexpressing a constitutively
active form of MEK1 (CAMEK1). As compared to mock-
transfected cells, CAMEK1 cells maintained ERK1/2 phos-
phorylation after 48 h in the absence of EGF (Figure 5a).
Interestingly, EGF deprivation did not result in the upregula-
tion of FLIPL in CAMEK1 cells, further supporting an inhibitory
role of the ERK1/2 pathway in the regulation of FLIPL
expression. Finally, we examined whether the EGFR-
mediated regulation of sensitivity to TRAIL was altered in
cells stably overexpressing CAMEK1. As shown in Figure 5b,
CAMEK1 cells, which maintained low cellular levels of FLIPL
even in the absence of EGF in the culture medium, were
 +/+ -/- -/+ -/+  +/+ -/- -/+ -/+EGF
UT LY
FLIPL
p-AKT
AKT
GAPDH
UT U0126
FLIPL
BimEL
pERK1/2
ERK1/2
Tubulin
0
20
40
60
80
NoTRAIL TRAIL
UT U0126
EGF +/+
A
po
pt
ot
ic
 c
el
ls
 (%
)
EGF
0
2
4
6
8
10
12
FL
IP
L 
m
R
N
A
(F
old
 E
xp
re
ss
ion
)
*** **
-/- -/+ -/+
UT U0126
EGF +/+ -/- -/+ -/+
Figure 4 Inhibition of the ERK1/2 pathway prevents FLIPL downregulation and
sensitivity to TRAIL induced by EGF. MCF10A cells were preincubated in the
absence of EGF for 48 h before re-addition of EGF ( /þ ) and incubated in
the presence or absence of (a) the PI3K inhibitor LY294002 (LY, 10 mM), or (b) the
MEK1 inhibitor U0126 (10 mM), for 15 h. Other cultures were incubated in parallel
with (þ /þ ) or without ( / ) EGF for the entire experimental period
(preincubation/incubation). FLIPL, p-AKT, AKT, p-ERK1/2, ERK1/2 and BimEL
levels were assessed by western blotting. GAPDH and tubulin levels were used as
protein loading controls. FLIPL mRNA levels were measured by quantitative PCR
(b, lower panel). Results are representative of two independent experiments.
(c) Cells were preincubated/incubated as in (b) and then TRAIL (500 ng/ml) was
added to some cultures for 6 h. Apoptosis was determined as described in Materials
and Methods. Error bars represent S.D. from three independent experiments.
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Figure 5 Constitutive activation of the ERK1/2 pathway abrogates EGF-
dependent regulation of FLIPL levels and sensitivity to TRAIL. (a) MCF10A cells
were infected with retroviruses encoding control vector (pBabe Mock) or a
CAMEK1. Following puromycin selection for stably infected lines, cells were grown
in the presence or absence of EGF for 48 h, and phosphorylated ERK1/2, total
ERK1/2, FLIPL, BimEL and MEK1 levels were assessed by western blotting.
GAPDH was used as a protein loading control. (b) Infected cells were incubated with
or without EGF for 48 h before treatment with TRAIL (500 ng/ml) for 6 h. Thereafter,
apoptosis was assessed as described in Materials and Methods. Error bars
represent S.D. from three independent experiments. *Po0.05
ERK1/2 controls FLIPL levels and TRAIL resistance
R Yerbes et al
1911
Cell Death and Differentiation
sensitive to TRAIL-induced apoptosis independently of EGFR
activation.
Role of c-myc in the control of FLIPL levels in MCF10A
cells by EGF. C-myc is a member of the Myc family
of transcription factors that plays a central role in regulating
cell growth, cell-cycle progression and apoptosis.27 C-myc is
regulated at both transcriptional and post-transcriptional
levels by the ERK1/2 pathway following activation of growth
factors receptors.16,28 It has also been reported that c-myc
could repress FLIP expression at the transcriptional level.29
To determine the role of c-myc in EGFR-mediated down-
regulation of FLIPL and sensitization to TRAIL-induced
apoptosis, we first examined the regulation by EGF
of c-myc protein levels in MCF10A cells. Results shown in
Figure 6a indicate that EGF deprivation resulted in the
inhibition of the ERK1/2 pathway and c-myc downregulation.
Moreover, re-addition of EGF to EGF-deprived cells triggered
the activation of the ERK1/2 pathway and the upregulation of
c-myc in an ERK1/2-dependent manner, both events follow-
ing an opposite pattern to FLIPL levels. To further investigate
the role of c-myc in the regulation of FLIPL levels by EGF, we
examined whether silencing c-myc expression could have an
impact on FLIPL levels in cells maintained in EGF-CM.
Results shown in Figure 6b indicate that c-myc knockdown
induced the expression of both FLIPL mRNA (left panel) and
protein (right panel) in cells grown in the presence of EGF.
As a complementary approach to further demonstrate the
role of c-myc in controlling FLIPL expression in EGF-deprived
cells, we generated MCF10A cells constitutively expressing
an Myc-ER chimera.30 In these cells, activity of the chimeric
myc protein is completely dependent on the addition of
exogenous 4-hydroxytamoxifen (4HT).31 As a positive control
of Myc-ER activation, we determined E2F-1 expression, a
transcription factor positively regulated by c-myc,32 in cells
treated with 4HT. As shown in Figure 6c, E2F-1 was
upregulated following Myc-ER activation by 4HT in EGF-
deprived cells. Interestingly, Myc-ER activation resulted in
FLIPL downregulation in MCF10A cells deprived of EGF,
at both the protein and mRNA levels (Figure 6c). Finally,
we analyzed the sensitivity to TRAIL-induced apoptosis in
cells in whichMyc-ERwas activated by 4HT. Results shown in
Figure 6d demonstrate that Myc-ER activation was sufficient
to sensitize EGF-deprived cells to TRAIL.
Transformation blocks FLIPL upregulation and TRAIL
resistance upon EGF deprivation in MCF10A cells: role
of the ERK1/2 pathway. To investigate the impact of cell
transformation on the regulation of FLIPL expression and
TRAIL sensitivity by EGF, we generated MCF10A cells that
expressed a constitutively active form of the oncogene
ERBB2/HER-2/neu.33 In cells overexpressing the ERBB2
(NeuT) protein, the ERK1/2 pathway was not inhibited upon
EGF withdrawal (Figure 7a). Consistent with this finding,
c-myc and FLIPL levels did not change in response to EGF
deprivation (Figure 7a). We next examined the regulation
by EGF of TRAIL-induced apoptosis in both mock and
NeuT-transduced cell lines. In contrast to what was observed
in mock-transduced cells, EGF deprivation did not reduce the
sensitivity to TRAIL in NeuT cells (Figure 7b), supporting the
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Figure 6 Role of c-myc in the control of FLIPL levels and TRAIL sensitivity by EGF. (a) MCF10A cells were cultured in the presence or absence of EGF during 48 h, and
then EGF was added for 24 h to EGF-deprived cells. P-ERK1/2, ERK1/2, c-myc and FLIPL levels (whole cell extracts) were analyzed by western blotting. GAPDH was used as
a protein loading control. Results are representative of three independent experiments. (b) MCF10A cells were transfected either with a small interfering RNA (siRNA)
oligonucleotide targeting c-myc or a scrambled oligonucleotide (Scr) for 48 h as described in Materials and Methods. FLIPL levels were assessed by quantitative PCR or
western blotting. C-myc knockdown was analyzed by western blotting. Results are representative of three independent experiments. GAPDH was used as a protein loading
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hypothesis that the constitutive activation of the ERK1/2
pathway and c-myc expression in these cells are responsible
for maintaining low FLIPL levels and sensitivity to TRAIL,
independently of EGF supply. Furthermore, incubation of
NeuT cells with the MEK1 inhibitor U0126 caused a marked
inhibition of ERK1/2 phosphorylation and downregulation of
c-myc expression (Figure 7c). Strikingly, U0126 treatment
clearly upregulated FLIPL expression (Figure 7c) and
reversed transformation-mediated sensitivity to TRAIL
(Figure 7d), independently of the presence of EGF in the
culture medium.
Discussion
Preclinical studies conducted in the past years have demon-
strated that TRAIL as well as agonistic antibodies against
TRAIL-R1 and TRAIL-R2 can efficiently induce apoptosis in
tumor cells, but not in themajority of normal cells.34,35 In many
of these preclinical studies, TRAIL-sensitive cell lines were
used and it has since become clear that some primary tumor
cells are TRAIL resistant.36 Moreover, it has been reported
that EGFR pathway activation limits TRAIL-induced apoptosis
in breast tumor cells19 and the small-molecule EGFR inhibitor
gefitinib reverses TRAIL resistance in other tumor cells.20 In
this respect, there are ongoing clinical trials using combination
of EGFR inhibitors and recombinant TRAIL.37 However, it is
rather unknown the effect that these combination treatments
may have in non-tumor cells. In our study, we demonstrate for
the first time that preventing EGFR signaling induces
resistance to TRAIL in non-tumor breast epithelial cells
through the upregulation of FLIPL and inhibition of TRAIL-
induced apical caspase-8 activation. Our recently published
data demonstrate that FLIPL knockdown activates apoptosis
by endogenous TRAIL in a DISC-dependent manner in the
presence of EGF and reduces the number of acini in 3D
basement-membrane cultures of MCF10A cells.25 Conver-
sely, FLIPL overexpression in MCF10A cells delays lumen
formation in these cultures.25 In this respect, it has been
reported that TRAIL is upregulated during morphogenesis of
MCF10A mammary epithelial cells in 3D cultures and
cooperates with Bcl-2 family proteins to regulate lumen
formation in MCF10A acini.38 During morphogenesis, the
cells in the center of the epithelial mass lack matrix
attachment, which leads to inhibition of EGFR signaling.26 In
accordance with our results, it would be predicted that loss of
EGFR signaling in the inner cells of the acini would induce
FLIPL expression and inhibit TRAIL-induced cell death.
Collectively, these results suggest that maintenance of
elevated FLIPL levels may have an important role in the
timely control of morphogenesis in the mammary gland by
preventing the early activation of TRAIL-induced cell death.
Of the signaling pathways activated upon engagement of
tyrosine kinase receptors by their ligands, two of them, the
PI3K/Akt and the MAPK/ERK pathways, are frequently
reported to play a survival role preventing the induction
of apoptosis.19,39 Furthermore, inhibition of PI3K/Akt40 or
MAPK/ERK41 increases the sensitivity of tumor cells to
TRAIL-induced apoptosis. In contrast, other studies have
shown that sensitivity to TRAIL can be enhanced upon
activation of the PI3K/Akt42 or ERK1/243 pathways, although
the underlying mechanisms have not been characterized. We
hereby report for the first time that in non-tumor human breast
epithelial cells, activation of the ERK1/2 MAPK pathway by
EGF is crucially involved in the sensitization of these cells to
TRAIL-induced apoptosis. Most of the studies examining the
regulation of TRAIL sensitivity by the PI3K/Akt and MAPK/
ERK pathways have been carried out in tumor cell lines
of different sources in which these signaling pathways
are commonly deregulated, leading to aberrant activation of
genes involved in cell survival, metabolism, proliferation and
migration.44 Moreover, it is well known that the number of
active cell surface receptors for growth factors can determine
whether ERK activation is transient or sustained, which
results in markedly different cellular responses.45 Therefore,
differences in cell surface EGFR levels may explain the
different outcome of EGFR activation on FLIP levels and
apoptosis sensitivity between normal and tumor cells.
Our results are in agreement with previous data indicating
that sensitivity of EGF-dependent non-tumor breast epithelial
cells to different apoptotic stimuli, including death receptor
ligands, is abrogated in three-dimensional cultures (3D).46
In these 3D cultures, formation of a polarized structure is
achieved and activation of the MAPK/ERK pathway by EGF is
markedly attenuated.46,47 Whether or not FLIPL levels
increase in 3D cultures need to be investigated. Interestingly,
non-polarized malignant breast epithelial cells maintain
an elevated MAPK/ERK pathway activation in response to
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Figure 7 Oncogenic transformation blocks FLIPL upregulation and TRAIL
resistance upon EGF deprivation in MCF10A cells. (a) MCF10A cells were infected
either with a retroviral control vector (Mock) or a retrovirus encoding a constitutively
active form of ERBB2 (NeuT). Following puromycin selection, cells were grown in
the presence or absence of EGF during 48 h and FLIPL, BimEL, ERK1/2, c-myc,
ERBB2 and GAPDH levels and phospho-ERK1/2 status were analyzed by western
blotting. Results are representative of three different experiments. (b) Infected cells
were incubated as in (a) before adding TRAIL (500 ng/ml) for 6 h. Apoptosis was
measured as described in Materials and Methods. Error bars represent S.D. from
three independent experiments. *Po0.05. (c) NeuT cells were incubated in the
presence or absence of EGF for 32 h. Following this incubation, the MEK1 inhibitor
U0126 (10mM) was added to some cultures and the cells were incubated for 16 h.
Following this incubation, cells were either collected and protein levels analyzed by
western blotting (c) or treated with TRAIL for 6 h to assess apoptosis (d). Error bars
represent S.D. from three independent experiments. **Po0.01
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EGF47 and remain sensitive to death receptor ligands in
3D cultures.46
Through the phosphorylation of both cytoplasmic signaling
proteins and transcription factors, activated ERK1/2 regulates
cell metabolism, survival, differentiation, proliferation and
migration. Among the transcription factors regulated by ERK,
the ternary complex factor plays an important role in inducing
the expression of immediate-early genes such as c-Fos and
c-Myc.48 In addition, activation of the ERK1/2 pathway
induces stabilization of the c-myc protein.49 Interestingly,
our data demonstrate that EGF-dependent activation of the
ERK1/2 pathway enhances c-Myc levels and negatively
regulates FLIPL expression in breast epithelial cells, and
sensitizes these cells to TRAIL-induced apoptosis. By using
either siRNA oligonucleotides to downregulate c-myc or the
estrogen activatable Myc-ER chimera, we have provided
further evidences supporting that c-myc plays a regulatory
role in the control of FLIPL levels by EGF, which are in
agreement with previous data indicating that c-myc binds and
represses the human FLIP promoter and sensitizes cells to
TRAIL.29 However, in tumor cells c-myc expression is
frequently dissociated from the ERK1/2 pathway, either by
mutation, reduced degradation through the ubiquitin–
proteasome system or by other mechanisms.49,50 Accord-
ingly, in tumor cells FLIPL levels could be regulated in an
ERK1/2-independent manner by other survival pathways.51
Our results also indicate that in EGF-deprived cells, c-myc
activation using a 4HT-activatable Myc-ER chimera does
not completely reproduce the sensitization achieved by EGF
re-addition, which suggests that other effectors downstream
of ERK1/2 activation could be also important for a complete
apoptotic response to TRAIL. In this respect, it has been
reported that c-Fos can function as a proapoptotic protein by
repressing the expression of FLIPL through binding to the
gene promoter.52 Alternatively, other signaling emerging from
the EGFR such as the p38-MAPK and the Jun N-terminal
kinase (JNK) pathways might downregulate FLIPL expression
by transcriptional and post-transcriptional mechanisms. Thus,
it has been demonstrated that EGFR-mediated activation of
the p38 pathway regulates the activity of the transcription
factor SP3,53 which under certain conditions could be a
negative regulator of the FLIPL gene promoter.
54 Moreover,
JNK activation by TNF-a reduces FLIPL stability by a
mechanism involving the JNK-mediated phosphorylation
and activation of the E3 ubiquitin ligase Itch, which ubiquiti-
nates FLIPL and induces its proteasomal degradation.
55
Overexpression of oncogenic receptor tyrosine kinases is a
common event in breast cancer. In particular, 15–30% of all
cases show elevated ERBB2,56 but despite the development
of ERBB2/HER2-targeted therapies, only 35% of ERBB2-
positive patients initially respond to those treatments. It
has been shown in experiments in vitro40 and in vivo57 that
combination of antibodies against ERBB2 and TRAIL recep-
tors facilitates apoptosis and tumor regression, although there
are data reporting that the apoptosis-inducing capacity of
these combinations is cell type-dependent.58 Our results
indicate that in ERBB2-overexpressing cells sensitivity to
TRAIL is controlled by the ERK1/2 pathway-mediated regula-
tion of FLIPL levels. These data suggest that amplification of
ERBB2 in tumor cells may have different outcomes regarding
sensitivity to TRAIL. On one hand, it may increase resistance
to TRAIL through ERBB2-induced activation of the PI3K/Akt
pathway.40 On the other hand, it may contribute to maintain
low FLIPL levels by ERK1/2-mediated activation of c-myc and
other genes,29,52 which may result in enhanced sensitivity to
TRAIL. This is not unique of ERBB2 as other oncoproteins
could also sensitize cells to TRAIL by activating the ERK1/2
pathway,59 although themechanism underlying this sensitiza-
tion has not been elucidated. Our data highlight the role of
the EGF-regulated, ERK1/2 pathway-mediated regulation of
FLIPL levels as an important mechanism modulating the
sensitivity of human breast epithelial cells to TRAIL-induced
apoptosis that may contribute, in concert with others, to the
differential sensitivity of normal and tumor cells to TRAIL.
At the same time, our results provide arguments for a cautious
clinical application of TRAIL in cancer patients, especially in
combination with agents that may inhibit the ERK1/2 pathway.
Materials and Methods
Reagents and antibodies. Recombinant human EGF was from Peprotech
(London, UK). Recombinant human TRAIL (residues 95–281) was produced as
described previously.60 U0126 and gefitinib were purchased from Selleck
Chemicals (Houston, TX, USA). Mouse anti-a-tubulin antibody, LY294002, 4HT,
hydrocortisone, transferrin and puromycin were obtained from Sigma-Aldrich
(St. Louis, MO, USA). Anti-caspase-8 was generously provided by Dr. Gerald
Cohen (Leicester University, Leicester, UK). Anti-FADD, anti-ERBB2 and anti-
E2F1 monoclonal antibodies were obtained from BD Biosciences (Erembodegem,
Belgium). GAPDH and c-myc monoclonal antibodies were from Santa Cruz
Technology (Santa Cruz, CA, USA). Anti-TRAIL-R2 and anti-c-FLIP monoclonal
antibody (NF6) were from Alexis Corporation (Lausen, Switzerland). Anti-TRAIL-
R1 and anti-TRAIL-R2 monoclonal antibodies for surface receptor analysis were
from Abcam (Cambridge, UK). Anti-pAKT, anti-AKT, anti-pERK1/2 and anti-MEK1
antibodies were obtained from Cell Signaling Technology (Temecula, CA, USA).
Anti-ERK antibody was from Upstate-Millipore (New York, NY, USA). Anti-Bim
polyclonal antibody was purchased from Calbiochem (Darmstadt, Germany).
Horseradish peroxidase or FITC-conjugated secondary antibodies, goat anti-
mouse and goat anti-rabbit were obtained from DAKO (Cambridge, UK).
Cell lines. MCF10A and MCF12A cell lines were maintained in DMEM/F12
supplemented with 5% donor horse serum, 2 mM L-glutamine, 20 ng of EGF per
ml, 10mg of insulin per ml, 100 ng of cholera toxin per ml, 0.5mg of hydrocortisone
per ml, 50 U of penicillin per ml and 50mg of streptomycin per ml at 37 1C in a 5%
CO2-humidified, 95% air incubator. The 184A1 cells were cultured in the same
medium with transferrin (5 mg/ml).
Determination of apoptosis. Cells (3 105 per well) were treated in
6-well plates as indicated in the figure legends. After treatment, hypodiploid
apoptotic cells were detected by flow cytometry according to published
procedures.60 Basically, cells were washed with phosphate-buffered saline
(PBS), fixed in cold 70% ethanol and then stained with propidium iodide while
treating with RNAse. Quantitative analysis of sub-G1 cells was carried out in a
FACSCalibur cytometer using the Cell Quest software (Becton Dickinson,
Mountain View, CA, USA).
Immunoblot analysis of proteins. Cells (3 105) were washed with
PBS and protein content was measured following cell lysis using the Bradford
reagent (Bio-Rad Laboratories, Hercules, CA, USA) before adding Laemmli
sample buffer. Where indicated, whole cell extracts were obtained. Samples
were sonicated, and proteins were resolved on SDS-polyacrylamide minigels and
detected as described previously.60
Analysis of TRAIL receptors by flow cytometry. MCF10A cells were
detached with RPMI/3 mM EDTA, and cytofluorimetric analysis of proteins was
performed as described previously.60 Briefly, cells were washed in ice-cold PBS,
and resuspended in PBS. Cells were then labeled with anti-TRAIL receptor
antibodies (5 mg/ml) or no antibody (negative control) and then incubated with goat
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anti-mouse FITC-conjugated antibody (F(ab)2 fragment). Labeled cells were
analyzed by flow cytometry using the Cell Quest software.
Real-time RT-PCR. Total RNA was isolated from MCF10A cells with the
Trizol reagent (Life Technologies, Grand Island, NY, USA) as recommended by
the supplier. Total RNA (2 mg) was used as a template for cDNA synthesis using
an RT-PCR kit (Perkin-Elmer, Waltham, MA, USA). mRNA expression was
analyzed in triplicate by quantitative RT-PCR on the ABI Prism7500 sequence
detection system using predesigned Assay-on-demand primers and probes
(Applied Biosystems, Carlsbad, CA, USA). mRNA expression was determined by
the comparative cycle threshold (Ct) method (DDCt). Hypoxanthine-guanine
phosphoribosyltransferase (HPRT Part Number 4331182 and HPRT1 Part
Number 4351370) was used as an internal control and mRNA expression levels
of FLIPL and cFLIPS were given as fraction of mRNA levels in control cells.
Primers and probes used were: cFLIPS forward, 5
0-CAGCAATCCAAAAGAGTCT-
CAAGGA-30; cFLIPS reverse, 50-AATTTTCAGATCAGGACAATGGGCATA-30;
probe FLIPS: 5
0-ACTTCAGGATGATAACACCC-30; for FLIPL we used either of
two different oligos and probes: FLIPL forward, 5
0-AGTGCCTCTCCCA-
GAAACTGA-30; FLIPL reverse, 50-GCTGTTCCAATCATACATGTAGCCATT-30;
probe FLIPL, 5
0-CAAGAAAGAAAACGCCCACTCC-30; FLIPL 2 forward, 50-GGCT
CCCCCTGCATCAC-30; FLIPL 2 reverse, 50-TTTGGCTTCCCTGCTAGATAAG
G-30; probe FLIPL 2, 50-CAGGAGGATGTTCATGGGAGATTCATGC-30.
RNA interference. siRNAs against FLIPL: 5
0-CCUAGGAAUCUGCCUGAU
AdTdT-30 and non-targeting scrambled siRNA were synthesized by Sigma
Proligo (St. Louis, MO, USA). siRNA against c-Myc was purchased from Qiagen
(Germantown, PA, USA) (FlexiTube). Cells were transfected with 50 nM siRNAs
using DharmaFECT-1 (Dharmacon, Lafayette, CA, USA) as described by the
manufacturer. After 24 h for FLIPL siRNA or 48 h for c-myc siRNA, transfection
medium was replaced with regular medium before further analysis.
Retroviral vectors and virus production. FLIPL (in pCR3.V64 vector, a
kind donation of Dr. J Tschopp, University of Lausanne) was cloned into BamHI/SalI
sites of pBabepuro. pBabepuro constitutively active MEK (S217E/S221E) was a gift
from Dr. CJ Marshall (Institute of Cancer Research, London, UK). pBabepuro-myc-
ER was donated by Dr. J Leo´n (Instituto de Biomedicina y Biotecnologı´a de
Cantabria, Santander, Spain). Constitutively active ErbB2 mutant (pBabe-NeuT) was
kindly provided by Danielle Carroll (Harvard Medical School, Boston, MA, USA).
Retroviruses for protein overexpression were produced by transfection of HEK293-T
cells by calcium phosphate method with the corresponding retroviral vectors.
Retrovirus-containing supernatants were collected 48 h after transfection and
concentrated by ultracentrifugation at 22 000 r.p.m. for 90 min at 41C.
Generation of MCF10A cell lines. MCF10A cells were plated at 3.5 105
cells per 10-cm dish and infected with the retroviruses mentioned above. Stable
populations were obtained by selection with 1.5mg/ml puromycin during 48 h.
Statistical Analysis. All data are presented as the mean±S.D. of at least
three independent experiments. The differences among different groups were
determined by the Student’s t-test. Po0.05 was considered significant.
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